Stockreport

H.C. Wainwright Affirms ‘Buy' Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects [Yahoo! Finance]

Atai Beckley N.V - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF Wainwright reiterated a ‘Buy' rating on the stock and a $15 price target. The positive stance follows a meeting between the research firm and the company's CEO, Srinivas [Read more]